Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.54 |
| ▸ | PI4KA | P42356 | 2/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.50 |
| ▸ | NSD3 | Q9BZ95 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NSD2 | O96028 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12948658 | 0.90 | ADORA2A (0.52) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL12948656 | 0.84 | ADORA2A (0.59) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL8846475 | 0.83 | ADORA2A (0.56) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL19841 | 0.79 | ADORA2A (0.69) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL12922454 | 0.79 | ADORA2A (0.55) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL8846480 | 0.79 | ADORA2A (0.51) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL986231 | 0.77 | ADORA2A (0.56) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL20621738 | 0.77 | ADORA2A (0.56) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL5077097 | 0.77 | ADORA2A (0.51) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL22142773 | 0.77 | ADORA2A (0.66) | ADORA2AADORA1ADORA2BPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868011-B2 | Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus | GENERAL ATOMICS (US) | 2011-01-11 | — | — | US | disclosed |
| US-20080194594-A1 | Use of reversible inhibitors of s-adenosyl-l-homocysteine hydrolase for treating lupus | NINGBO ZIYUAN PHARMACEUTICALS, INC. (CN) | 2008-08-14 | — | — | US | disclosed |
| US-20070207172-A1 | Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus | NINGBO ZIYUAN PHARMACEUTICALS, INC. (CN) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207172-A1 | Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus | AHCY, AHCYL1, BHMT | ADORA2A 70/4885ADORA1 95/4885ADORA2B 206/4885 |
| US-20080194594-A1 | Use of reversible inhibitors of s-adenosyl-l-homocysteine hydrolase for treating lupus | AHCY, AHCYL1, BHMT | ADORA2A 70/4885ADORA1 95/4885ADORA2B 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.